Sangamo BioSciences, Inc.-Product Pipeline Review-2015

Sangamo BioSciences, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC07260CDB
  • |
  • Pages: 55
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Sangamo BioSciences, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Sangamo BioSciences, Inc.-Product Pipeline Review-2015', provides an overview of the Sangamo BioSciences, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sangamo BioSciences, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Sangamo BioSciences, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Sangamo BioSciences, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Sangamo BioSciences, Inc.'s pipeline products

Reasons To Buy

Evaluate Sangamo BioSciences, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Sangamo BioSciences, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Sangamo BioSciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Sangamo BioSciences, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sangamo BioSciences, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Sangamo BioSciences, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Sangamo BioSciences, Inc. Snapshot 6

Sangamo BioSciences, Inc. Overview 6

Key Information 6

Key Facts 6

Sangamo BioSciences, Inc.-Research and Development Overview 7

Key Therapeutic Areas 7

Sangamo BioSciences, Inc.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Sangamo BioSciences, Inc.-Pipeline Products Glance 12

Sangamo BioSciences, Inc.-Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Phase I Products/Combination Treatment Modalities 13

Sangamo BioSciences, Inc.-Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Discovery Products/Combination Treatment Modalities 15

Sangamo BioSciences, Inc.-Drug Profiles 16

CERE-110 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

SB-728T 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Stem Cell Therapy to Activate CCR5 for HIV 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Gene Therapy for Hemophilia A 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Gene Therapy for Huntington's Disease 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Gene Therapy for Lung Diseases 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Gene Therapy for Sickle Cell Disease 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Gene Therapy for X-Linked SCID 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Gene Therapy to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

SB-318 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

SB-728 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

SB-913 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

SBLSD-3 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

SBLSD-4 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

SHP-624 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Stem Cell Therapy for Beta Thalassemia 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Stem Cell Therapy to Activate CXCR4 for HIV 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Gene Therapy for Monogenic Diseases 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Sangamo BioSciences, Inc.-Pipeline Analysis 36

Sangamo BioSciences, Inc.-Pipeline Products by Target 36

Sangamo BioSciences, Inc.-Pipeline Products by Route of Administration 37

Sangamo BioSciences, Inc.-Pipeline Products by Molecule Type 38

Sangamo BioSciences, Inc.-Pipeline Products by Mechanism of Action 39

Sangamo BioSciences, Inc.-Recent Pipeline Updates 40

Sangamo BioSciences, Inc.-Dormant Projects 49

Sangamo BioSciences, Inc.-Discontinued Pipeline Products 50

Discontinued Pipeline Product Profiles 50

SB-509 50

Sangamo BioSciences, Inc.-Company Statement 51

Sangamo BioSciences, Inc.-Locations And Subsidiaries 53

Head Office 53

Other Locations & Subsidiaries 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

Sangamo BioSciences, Inc., Key Information 6

Sangamo BioSciences, Inc., Key Facts 6

Sangamo BioSciences, Inc.-Pipeline by Indication, 2015 9

Sangamo BioSciences, Inc.-Pipeline by Stage of Development, 2015 10

Sangamo BioSciences, Inc.-Monotherapy Products in Pipeline, 2015 11

Sangamo BioSciences, Inc.-Phase II, 2015 12

Sangamo BioSciences, Inc.-Phase I, 2015 13

Sangamo BioSciences, Inc.-Preclinical, 2015 14

Sangamo BioSciences, Inc.-Discovery, 2015 15

Sangamo BioSciences, Inc.-Pipeline by Target, 2015 36

Sangamo BioSciences, Inc.-Pipeline by Route of Administration, 2015 37

Sangamo BioSciences, Inc.-Pipeline by Molecule Type, 2015 38

Sangamo BioSciences, Inc.-Pipeline Products by Mechanism of Action, 2015 39

Sangamo BioSciences, Inc.-Recent Pipeline Updates, 2015 40

Sangamo BioSciences, Inc.-Dormant Developmental Projects,2015 49

Sangamo BioSciences, Inc.-Discontinued Pipeline Products, 2015 50

Sangamo BioSciences, Inc., Subsidiaries 53

List of Figures

Sangamo BioSciences, Inc.-Pipeline by Top 10 Indication, 2015 8

Sangamo BioSciences, Inc.-Pipeline by Stage of Development, 2015 10

Sangamo BioSciences, Inc.-Monotherapy Products in Pipeline, 2015 11

Sangamo BioSciences, Inc.-Pipeline by Top 10 Target, 2015 36

Sangamo BioSciences, Inc.-Pipeline by Top 10 Route of Administration, 2015 37

Sangamo BioSciences, Inc.-Pipeline by Top 10 Molecule Type, 2015 38

Sangamo BioSciences, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Sangamo BioSciences, Inc.; Sangamo BioSciences, Inc. - Key Therapeutics; Sangamo BioSciences, Inc. - Pipeline Overview and Promising Molecules; Sangamo BioSciences, Inc. - News; Sangamo BioSciences, Inc. - Latest Updates; Sangamo BioSciences, Inc. - Pipeline; Sangamo BioSciences, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 97335
Site License
USD 3000 INR 194670
Corporate User License
USD 4500 INR 292005



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]